Brian Blagg, Ph.D. - Publications

2003- Chemistry University of Kansas, Lawrence, KS, United States 

189 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Pipalia NH, Saad SZ, Subramanian K, Cross A, Al-Motawa A, Garg K, Blagg BSJ, Neckers L, Helquist P, Wiest O, Ory DS, Maxfield FR. HSP90 inhibitors reduce cholesterol storage in Niemann-Pick type C1 mutant fibroblasts. Journal of Lipid Research. 100114. PMID 34481829 DOI: 10.1016/j.jlr.2021.100114  1
2021 Blagg B, Chaudhury S, Meka PN, Banerjee M, Kent CN. Structure-based design, synthesis, and biological evaluation of Hsp90β-selective inhibitors. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 34449940 DOI: 10.1002/chem.202102574  1
2021 Rodriguez YA, Kaur S, Nolte E, Zheng Z, Blagg BSJ, Dobrowsky RT. Novologue Therapy Requires Heat Shock Protein 70 and Thioredoxin-Interacting Protein to Improve Mitochondrial Bioenergetics and Decrease Mitophagy in Diabetic Sensory Neurons. Acs Chemical Neuroscience. PMID 34340312 DOI: 10.1021/acschemneuro.1c00340  1
2021 Serwetnyk MA, Blagg BSJ. The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition. Acta Pharmaceutica Sinica. B. 11: 1446-1468. PMID 34221862 DOI: 10.1016/j.apsb.2020.11.015  0.01
2021 Zhou J, Gelot C, Pantelidou C, Li A, Yücel H, Davis RE, Farkkila A, Kochupurakkal B, Syed A, Shapiro GI, Tainer JA, Blagg BSJ, Ceccaldi R, D'Andrea AD. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nature Cancer. 2: 598-610. PMID 34179826 DOI: 10.1038/s43018-021-00203-x  1
2021 Sanchez JN, Subramanian C, Chanda M, Shanguan G, Zhang N, Wang T, Timmermann BN, Blagg BSJ, Cohen MS. A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas. Melanoma Research. 31: 197-207. PMID 33904516 DOI: 10.1097/CMR.0000000000000734  1
2021 Tosh DK, Brackett CM, Jung YH, Gao ZG, Banerjee M, Blagg BSJ, Jacobson KA. Biological Evaluation of 5'-(-Ethylcarboxamido)adenosine Analogues as Grp94-Selective Inhibitors. Acs Medicinal Chemistry Letters. 12: 373-379. PMID 33738064 DOI: 10.1021/acsmedchemlett.0c00509  1
2021 Blagg B, Mishra S, Khandelwal A, Bannerjee M, Balch M, Peng S, Davis R, Merfeld T, Menthali V, Deng J, Matts R. Selective Inhibition of the Hsp90a isoform. Angewandte Chemie (International Ed. in English). PMID 33621416 DOI: 10.1002/anie.202015422  1
2021 van Oosten-Hawle P, Bergink S, Blagg B, Brodsky J, Edkins A, Freeman B, Genest O, Hendershot L, Kampinga H, Johnson J, De Maio A, Masison D, Morano K, Multhoff G, Prodromou C, et al. First Virtual International Congress on Cellular and Organismal Stress Responses, November 5-6, 2020. Cell Stress & Chaperones. PMID 33559835 DOI: 10.1007/s12192-021-01192-7  1
2021 Mishra SJ, Liu W, Beebe K, Banerjee M, Kent CN, Munthali V, Koren J, Taylor JA, Neckers LM, Holzbeierlein J, Blagg BSJ. The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with -Hsp90 Inhibition. Journal of Medicinal Chemistry. PMID 33428418 DOI: 10.1021/acs.jmedchem.0c01700  1
2020 Banerjee M, Hatial I, Keegan BM, Blagg BSJ. Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases. Pharmacology & Therapeutics. 107747. PMID 33245994 DOI: 10.1016/j.pharmthera.2020.107747  1
2020 Brackett CM, García-Casas A, Castillo-Lluva S, Blagg BSJ. Synthesis and Evaluation of Ginkgolic Acid Derivatives as SUMOylation Inhibitors. Acs Medicinal Chemistry Letters. 11: 2221-2226. PMID 33214832 DOI: 10.1021/acsmedchemlett.0c00353  1
2020 Tomašič T, Durcik M, Keegan BM, Skledar DG, Zajec Ž, Blagg BSJ, Bryant SD. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations. International Journal of Molecular Sciences. 21. PMID 32962253 DOI: 10.3390/ijms21186898  1
2020 Patel BA, D'Amico TL, Blagg BSJ. Natural products and other inhibitors of FF ATP synthase. European Journal of Medicinal Chemistry. 207: 112779. PMID 32942072 DOI: 10.1016/j.ejmech.2020.112779  0.01
2020 Chaudhury S, Keegan BM, Blagg BSJ. The role and therapeutic potential of Hsp90, Hsp70, and smaller heat shock proteins in peripheral and central neuropathies. Medicinal Research Reviews. PMID 32844464 DOI: 10.1002/med.21729  1
2020 Pugh KW, Zhang Z, Wang J, Xu X, Munthali V, Zuo A, Blagg BSJ. From Bacteria to Cancer: A Benzothiazole-Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C-Terminal Inhibition. Acs Medicinal Chemistry Letters. 11: 1535-1538. PMID 32832020 DOI: 10.1021/Acsmedchemlett.0C00100  1
2020 Brackett CM, Blagg BSJ. Current Status of SUMOylation Inhibitors. Current Medicinal Chemistry. PMID 32778019 DOI: 10.2174/0929867327666200810135039  1
2020 Subramanian C, Gorney R, Wang T, Ge D, Zhang N, Zuo A, Blagg BSJ, Cohen MS. A novel heat shock protein inhibitor KU757 with efficacy in lenvatinib-resistant follicular thyroid cancer cells overcomes up-regulated glycolysis in drug-resistant cells in vitro. Surgery. PMID 32718802 DOI: 10.1016/J.Surg.2020.06.009  1
2020 Stine C, Coleman DL, Flohrschutz AT, Thompson AL, Mishra S, Blagg BS, Largent-Milnes TM, Lei W, Streicher JM. Heat shock protein 90 inhibitors block the antinociceptive effects of opioids in mouse chemotherapy-induced neuropathy and cancer bone pain models. Pain. 161: 1798-1807. PMID 32701840 DOI: 10.1097/J.Pain.0000000000001886  1
2020 Birar VC, Gelis I, Zuo A, Blagg BSJ. Synthesis of paramagnetic ligands that target the C-terminal binding site of Hsp90. Bioorganic & Medicinal Chemistry Letters. 30: 127303. PMID 32631523 DOI: 10.1016/J.Bmcl.2020.127303  1
2020 Duron DI, Lei W, Barker NK, Stine C, Mishra S, Blagg BSJ, Langlais PR, Streicher JM. Inhibition of Hsp90 in the spinal cord enhances the antinociceptive effects of morphine by activating an ERK-RSK pathway. Science Signaling. 13. PMID 32371496 DOI: 10.1126/Scisignal.Aaz1854  1
2020 Stine C, Coleman DL, Flohrschutz AT, Thompson AL, Mishra S, Blagg BS, Largent-Milnes TM, Lei W, Streicher JM. Heat shock protein 90 inhibitors block the anti-nociceptive effects of opioids in mouse chemotherapy-induced neuropathy and cancer bone pain models. Pain. PMID 32301839 DOI: 10.1097/j.pain.0000000000001886  1
2020 Koren J, Blagg BSJ. The Right Tool for the Job: An Overview of Hsp90 Inhibitors. Advances in Experimental Medicine and Biology. 1243: 135-146. PMID 32297216 DOI: 10.1007/978-3-030-40204-4_9  0.01
2020 Subramanian C, Grogan PT, Wang T, Bazzill J, Zuo A, White PT, Kalidindi A, Kuszynski D, Wang G, Blagg BSJ, Cohen MS. Novel C-terminal heat shock protein 90 inhibitors target breast cancer stem cells and block migration, self-renewal, and epithelial-mesenchymal transition. Molecular Oncology. PMID 32255264 DOI: 10.1002/1878-0261.12686  1
2020 Hilton MJ, Brackett CM, Mercado BQ, Blagg BSJ, Miller SJ. Catalysis-Enabled Access to Cryptic Geldanamycin Oxides. Acs Central Science. 6: 426-435. PMID 32232143 DOI: 10.1021/Acscentsci.0C00024  1
2020 Jackson JW, Rivera-Marquez G, Beebe K, Tran AD, Trepel JB, Gestwicki JE, Blagg BSJ, Ohkubo S, Neckers LM. Pharmacologic dissection of the overlapping impact of heat shock protein family members on platelet function. Journal of Thrombosis and Haemostasis : Jth. PMID 32022992 DOI: 10.1111/Jth.14758  1
2019 Kaur J, Bhardwaj A, Melancon BJ, Blagg BSJ. The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor. Synthetic Communications. 49: 1436-1443. PMID 33093687 DOI: 10.1080/00397911.2019.1602654  0.01
2019 Lei W, Duron DI, Stine C, Mishra S, Blagg BSJ, Streicher JM. The Alpha Isoform of Heat Shock Protein 90 and the Co-chaperones p23 and Cdc37 Promote Opioid Anti-nociception in the Brain. Frontiers in Molecular Neuroscience. 12: 294. PMID 31849607 DOI: 10.3389/Fnmol.2019.00294  1
2019 Sanchez J, Carter TR, Cohen MS, Blagg BS. Old and New Approaches to Target the Hsp90 Chaperone. Current Cancer Drug Targets. PMID 31793427 DOI: 10.2174/1568009619666191202101330  1
2019 Zhang Z, Banerjee M, Davis RE, Blagg BSJ. Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity. Bioorganic & Medicinal Chemistry Letters. 126676. PMID 31591016 DOI: 10.1016/j.bmcl.2019.126676  1
2019 Wang T, Subramanian C, Blagg BSJ, Cohen MS. A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression. Surgery. PMID 31561992 DOI: 10.1016/j.surg.2019.06.052  1
2019 Shi T, Wijeratne EMK, Solano C, Ambrose AJ, Ross AB, Norwood CR, Orido CK, Grigoryan T, Tillotson J, Kang M, Luo G, Keegan BM, Hu W, Blagg BSJ, Zhang DD, et al. An isoform-selective PTP1B inhibitor derived from nitrogen-atom augmentation of radicicol. Biochemistry. PMID 31298844 DOI: 10.1021/Acs.Biochem.9B00499  1
2019 Chatterjee BK, Jayaraj A, Kumar V, Blagg B, Davis RE, Jayaram B, Deep S, Chaudhuri TK. Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32. The Journal of Biological Chemistry. PMID 30792306 DOI: 10.1074/Jbc.Ra118.002502  1
2019 Kuravi S, Parrott E, Mudduluru G, Cheng J, Ganguly S, Saunthararajah Y, Jensen RA, Blagg BS, McGuirk JP, Balusu R. CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas. Blood Cancer Journal. 9: 14. PMID 30696805 DOI: 10.1038/S41408-019-0171-2  0.01
2018 You Z, Zhang Z, Blagg BSJ, Dobrowsky RT. KU-596 decreases mitochondrial superoxide and improves bioenergetics following downregulation of manganese superoxide dismutase in diabetic sensory neurons. Experimental Neurology. PMID 30557564 DOI: 10.1016/J.Expneurol.2018.12.006  1
2018 Kumar Mv V, Ebna Noor R, Davis RE, Zhang Z, Sipavicius E, Keramisanou D, Blagg BSJ, Gelis I. Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain. Medchemcomm. 9: 1323-1331. PMID 30151087 DOI: 10.1039/c8md00151k  1
2018 Zhang Z, You Z, Dobrowsky RT, Blagg BSJ. Synthesis and evaluation of a ring-constrained Hsp90 C-terminal inhibitor that exhibits neuroprotective activity. Bioorganic & Medicinal Chemistry Letters. PMID 29759728 DOI: 10.1016/J.Bmcl.2018.03.071  1
2018 Forsberg LK, Davis RE, Wimalasena VK, Blagg BSJ. Exploiting polarity and chirality to probe the Hsp90 C-terminus. Bioorganic & Medicinal Chemistry. PMID 29720349 DOI: 10.1016/j.bmc.2018.04.028  1
2018 Sheehan A, Messer AE, Papadaki M, Choudhry A, Kren V, Biedermann D, Blagg B, Khandelwal A, Marston SB. Molecular Defects in Cardiac Myofilament Ca-Regulation Due to Cardiomyopathy-Linked Mutations Can Be Reversed by Small Molecules Binding to Troponin. Frontiers in Physiology. 9: 243. PMID 29636697 DOI: 10.1016/J.Yjmcc.2018.07.019  1
2018 Que NLS, Crowley VM, Duerfeldt AS, Zhao J, Kent CN, Blagg BSJ, Gewirth DT. Structure based design of a Grp94-selective inhibitor: Exploiting a key residue in Grp94 to optimize paralog-selective binding. Journal of Medicinal Chemistry. PMID 29528635 DOI: 10.1021/Acs.Jmedchem.7B01608  1
2018 Byrd KM, Blagg BSJ. Chaperone substrate provides missing link for cancer drug discovery. The Journal of Biological Chemistry. 293: 2381-2382. PMID 29453286 DOI: 10.1074/jbc.H118.001591  1
2018 Huard DJ, Crowley VM, Du Y, Cordova RA, Sun Z, Tomlin MO, Dickey CA, Koren J, Blair L, Fu H, Blagg BSJ, Lieberman RL. Trifunctional high-throughput screen identifies promising scaffold to inhibit Grp94 and treat myocilin-associated glaucoma. Acs Chemical Biology. PMID 29402077 DOI: 10.1021/Acschembio.7B01083  1
2018 Neckers L, Blagg B, Haystead T, Trepel JB, Whitesell L, Picard D. Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development. Cell Stress & Chaperones. PMID 29392504 DOI: 10.1007/S12192-018-0877-2  1
2018 Khandelwal A, Kent CN, Balch M, Peng S, Mishra SJ, Deng J, Day VW, Liu W, Subramanian C, Cohen M, Holzbeierlein JM, Matts R, Blagg BSJ. Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor. Nature Communications. 9: 425. PMID 29382832 DOI: 10.1038/S41467-017-02013-1  1
2017 Stothert AR, Suntharalingam A, Tang X, Crowley VM, Mishra SJ, Webster JM, Nordhues BA, Huard DJE, Passaglia CL, Lieberman RL, Blagg BSJ, Blair LJ, Koren J, Dickey CA. Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma. Scientific Reports. 7: 17951. PMID 29263415 DOI: 10.1038/S41598-017-18344-4  1
2017 Forsberg LK, Anyika M, You Z, Emery S, McMullen M, Dobrowsky RT, Blagg BSJ. Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects. European Journal of Medicinal Chemistry. PMID 29137866 DOI: 10.1016/J.Ejmech.2017.10.038  1
2017 Zhang X, Li C, Fowler SC, Zhang Z, Blagg BSJ, Dobrowsky RT. Targeting Heat Shock Protein 70 to Ameliorate c-Jun Expression and Improve Demyelinating Neuropathy. Acs Chemical Neuroscience. PMID 29120605 DOI: 10.1021/Acschemneuro.7B00377  1
2017 Byrd K, Kent C, Blagg B. Synthesis and biological evaluation of stilbene analogs as Hsp90 C-terminal inhibitors. Chemmedchem. PMID 29058824 DOI: 10.1002/cmdc.201700630  0.64
2017 Khandelwal A, Crowley VM, Blagg BSJ. Resorcinol-Based Grp94-Selective Inhibitors. Acs Medicinal Chemistry Letters. 8: 1013-1018. PMID 29057043 DOI: 10.1021/acsmedchemlett.7b00193  1
2017 Forsberg L, Garg G, Zhao H, Blagg B. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 28940589 DOI: 10.1002/chem.201703206  1
2017 Crowley V, Huard D, Lieberman R, Blagg B. Second Generation Grp94-selective Inhibitors Provide Opportunities for the Inhibition of Metastatic Cancer. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 28857290 DOI: 10.1002/Chem.201703398  1
2017 Forsberg LK, Liu W, Holzbeierlein J, Blagg BSJ. Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer. Bioorganic & Medicinal Chemistry Letters. PMID 28844386 DOI: 10.1016/j.bmcl.2017.07.030  1
2017 Shelton LB, Baker JD, Zheng D, Sullivan LE, Solanki PK, Webster JM, Sun Z, Sabbagh JJ, Nordhues BA, Koren J, Ghosh S, Blagg BSJ, Blair LJ, Dickey CA. Hsp90 activator Aha1 drives production of pathological tau aggregates. Proceedings of the National Academy of Sciences of the United States of America. PMID 28827321 DOI: 10.1073/Pnas.1707039114  1
2017 Davis RE, Zhang Z, Blagg BSJ. A Scaffold Merging Approach to Hsp90 C-terminal Inhibition: Synthesis and Evaluation of a Chimeric Library. Medchemcomm. 8: 593-598. PMID 28533894 DOI: 10.1039/C6MD00377J  1
2017 Sofis MJ, Jarmolowicz DP, Kaplan SV, Gehringer RC, Lemley SM, Blagg BS, Johnson MA. KU32 Prevents 5-Fluorouracil Induced Cognitive Impairment. Behavioural Brain Research. PMID 28359881 DOI: 10.1016/J.Bbr.2017.03.042  0.01
2016 Mishra SJ, Ghosh S, Stothert AR, Dickey CA, Blagg BS. Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold. Acs Chemical Biology. PMID 27959508 DOI: 10.1021/Acschembio.6B00747  1
2016 Garg G, Zhao H, Blagg BS. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors. Bioorganic & Medicinal Chemistry. PMID 27914946 DOI: 10.1016/J.Bmc.2016.11.030  1
2016 Ghosh S, Liu Y, Garg G, Anyika M, McPherson NT, Ma J, Dobrowsky RT, Blagg BS. Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail. Acs Medicinal Chemistry Letters. 7: 813-8. PMID 27563408 DOI: 10.1021/Acsmedchemlett.6B00224  1
2016 Byrd KM, Subramanian C, Sanchez J, Motiwala HF, Liu W, Cohen MS, Holzbeierlein J, Blagg BS. Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 27037933 DOI: 10.1002/chem.201504955  1
2016 Crowley VM, Khandelwal A, Mishra S, Stothert AR, Huard DJ, Zhao J, Muth A, Duerfeldt AS, Kizziah JL, Lieberman RL, Dickey CA, Blagg BS. Development of Glucose Regulated Protein 94-Selective Inhibitors based on the BnIm and Radamide Scaffold. Journal of Medicinal Chemistry. PMID 27003516 DOI: 10.1021/Acs.Jmedchem.6B00085  1
2016 Di XJ, Wang YJ, Han DY, Fu YL, Duerfeldt AS, Blagg BS, Mu TW. Grp94 Delivers γ-aminobutyric Acid Type A (GABAA) Receptors to Hrd1-Mediatd Endoplasmic Reticulum-Associated Degradation. The Journal of Biological Chemistry. PMID 26945068 DOI: 10.1074/Jbc.M115.705004  1
2016 Garg G, Khandelwal A, Blagg BS. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects. Advances in Cancer Research. 129: 51-88. PMID 26916001 DOI: 10.1016/bs.acr.2015.12.001  1
2016 Ghosh S, Shinogle HE, Galeva NA, Dobrowsky RT, Blagg BS. Endoplasmic Reticulum Resident Heat Shock Protein 90 (Hsp90) Isoform Glucose-Regulated Protein 94 (Grp94) Regulates Cell Polarity and Cancer Cell Migration by Affecting Intracellular Transport. The Journal of Biological Chemistry. PMID 26872972 DOI: 10.1074/Jbc.M115.688374  1
2016 Anyika M, McMullen M, Forsberg LK, Dobrowsky RT, Blagg BS. Development of Noviomimetics as C-Terminal Hsp90 Inhibitors. Acs Medicinal Chemistry Letters. 7: 67-71. PMID 26819668 DOI: 10.1021/Acsmedchemlett.5B00331  1
2016 Hall J, Seedarala S, Zhao H, Garg G, Ghosh S, Blagg BS. Novobiocin Analogs That Inhibit the MAPK Pathway. Journal of Medicinal Chemistry. PMID 26745854 DOI: 10.1021/Acs.Jmedchem.5B01354  1
2016 Robinson PJ, Patel S, Liu X, Zhang Y, Khandelwal A, Blagg B, Casadei B, Watkins H, Redwood C. Novel Potential Treatment of Familial Hypertrophic Cardiomyopathy with Analogues of the Green Tea Polyphenol Epigallocatechin-3-Gallate Biophysical Journal. 110. DOI: 10.1016/J.Bpj.2015.11.719  1
2015 White PT, Subramanian C, Zhu Q, Zhang H, Zhao H, Gallagher R, Timmermann BN, Blagg BS, Cohen MS. Novel HSP90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion. Surgery. PMID 26542767 DOI: 10.1016/J.Surg.2015.07.050  1
2015 Dunn DM, Woodford MR, Truman AW, Jensen SM, Schulman J, Caza T, Remillard TC, Loiselle D, Wolfgeher D, Blagg BS, Franco L, Haystead TA, Daturpalli S, Mayer MP, Trepel JB, et al. c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells. Cell Reports. 12: 1006-18. PMID 26235616 DOI: 10.1016/J.Celrep.2015.07.004  1
2015 Ma J, Pan P, Anyika M, Blagg BS, Dobrowsky RT. Modulating Molecular Chaperones Improves Mitochondrial Bioenergetics and Decreases the Inflammatory Transcriptome in Diabetic Sensory Neurons. Acs Chemical Neuroscience. PMID 26161583 DOI: 10.1021/Acschemneuro.5B00165  1
2015 Khandelwal A, Crowley VM, Blagg BS. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside? Medicinal Research Reviews. PMID 26010985 DOI: 10.1002/med.21351  1
2015 Liu W, Vielhauer GA, Holzbeierlein JM, Zhao H, Ghosh S, Brown D, Lee E, Blagg BS. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells. Molecular Pharmacology. 88: 121-30. PMID 25939977 DOI: 10.1124/Mol.114.097303  1
2015 Hall JA, Seedarala S, Rice N, Kopel L, Halaweish F, Blagg BS. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery. Journal of Natural Products. 78: 873-9. PMID 25756299 DOI: 10.1021/Acs.Jnatprod.5B00054  1
2015 Alontaga AY, Li Y, Chen CH, Ma CT, Malany S, Key DE, Sergienko E, Sun Q, Whipple DA, Matharu DS, Li B, Vega R, Li YJ, Schoenen FJ, Blagg BS, et al. Design of high-throughput screening assays and identification of a SUMO1-specific small molecule chemotype targeting the SUMO-interacting motif-binding surface. Acs Combinatorial Science. 17: 239-46. PMID 25719760 DOI: 10.1021/co500181b  1
2015 Garg G, Zhao H, Blagg BS. Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors. Acs Medicinal Chemistry Letters. 6: 204-9. PMID 25699150 DOI: 10.1021/Ml5004475  1
2015 Zhao H, Garg G, Zhao J, Moroni E, Girgis A, Franco LS, Singh S, Colombo G, Blagg BS. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors. European Journal of Medicinal Chemistry. 89: 442-66. PMID 25462258 DOI: 10.1016/J.Ejmech.2014.10.034  1
2015 Ghosh S, Shinogle HE, Garg G, Vielhauer GA, Holzbeierlein JM, Dobrowsky RT, Blagg BS. Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells. Acs Chemical Biology. 10: 577-90. PMID 25402753 DOI: 10.1021/Cb5008713  1
2014 Hall JA, Forsberg LK, Blagg BS. Alternative approaches to Hsp90 modulation for the treatment of cancer. Future Medicinal Chemistry. 6: 1587-605. PMID 25367392 DOI: 10.4155/fmc.14.89  1
2014 Zhao J, Zhao H, Hall JA, Brown D, Brandes E, Bazzill J, Grogan PT, Subramanian C, Vielhauer G, Cohen MS, Blagg BS. Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors. Medchemcomm. 5: 1317-1323. PMID 25328661 DOI: 10.1039/C4Md00102H  1
2014 Muth A, Crowley V, Khandelwal A, Mishra S, Zhao J, Hall J, Blagg BS. Development of radamide analogs as Grp94 inhibitors. Bioorganic & Medicinal Chemistry. 22: 4083-98. PMID 25027801 DOI: 10.1016/J.Bmc.2014.05.075  1
2014 Stothert AR, Suntharalingam A, Huard DJ, Fontaine SN, Crowley VM, Mishra S, Blagg BS, Lieberman RL, Dickey CA. Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma. Human Molecular Genetics. 23: 6470-80. PMID 25027323 DOI: 10.1093/Hmg/Ddu367  1
2014 Zhao H, Anyika M, Girgis A, Blagg BS. Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines. Bioorganic & Medicinal Chemistry Letters. 24: 3633-7. PMID 24953820 DOI: 10.1016/J.Bmcl.2014.05.020  1
2014 Zhao H, Moroni E, Colombo G, Blagg BS. Identification of a new scaffold for hsp90 C-terminal inhibition. Acs Medicinal Chemistry Letters. 5: 84-8. PMID 24900777 DOI: 10.1021/Ml400404S  1
2014 Davenport J, Balch M, Galam L, Girgis A, Hall J, Blagg BS, Matts RL. High-throughput screen of natural product libraries for hsp90 inhibitors. Biology. 3: 101-38. PMID 24833337 DOI: 10.3390/Biology3010101  1
2014 Kusuma BR, Khandelwal A, Gu W, Brown D, Liu W, Vielhauer G, Holzbeierlein J, Blagg BS. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors. Bioorganic & Medicinal Chemistry. 22: 1441-9. PMID 24461493 DOI: 10.1016/j.bmc.2013.12.056  1
2014 Hall JA, Kusuma BR, Brandt GE, Blagg BS. Cruentaren A binds F1F0 ATP synthase to modulate the Hsp90 protein folding machinery. Acs Chemical Biology. 9: 976-85. PMID 24450340 DOI: 10.1021/cb400906e  1
2014 Moroni E, Zhao H, Blagg BS, Colombo G. Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities. Journal of Chemical Information and Modeling. 54: 195-208. PMID 24397468 DOI: 10.1021/Ci4005767  1
2014 Ma J, Farmer KL, Pan P, Urban MJ, Zhao H, Blagg BS, Dobrowsky RT. Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy. The Journal of Pharmacology and Experimental Therapeutics. 348: 281-92. PMID 24263156 DOI: 10.1124/Jpet.113.210435  1
2014 Patwardhan CA, Peterson LB, Blagg B, Chadli A. Abstract 3197: Gedunin inactivates the co-chaperone p23 causing cancer cell death by apoptosis Cancer Research. 74: 3197-3197. DOI: 10.1158/1538-7445.Am2014-3197  1
2014 Robinson P, Liu X, Zhang YH, Khandelwal A, Blagg B, Casadei B, Watkins H, Redwood C. P123The rescue of Ca2+ cycling abnormalities conferred by HCM-causing mutations with analogues of the green tea polyphenol epigallocatechin-3-gallate Cardiovascular Research. 103. DOI: 10.1093/Cvr/Cvu082.63  1
2013 Sadikot T, Swink M, Eskew JD, Brown D, Zhao H, Kusuma BR, Rajewski RA, Blagg BS, Matts RL, Holzbeierlein JM, Vielhauer GA. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay and Drug Development Technologies. 11: 478-88. PMID 24127661 DOI: 10.1089/Adt.2012.498  1
2013 Khandelwal A, Hall JA, Blagg BS. Synthesis and structure-activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor. The Journal of Organic Chemistry. 78: 7859-84. PMID 23834230 DOI: 10.1021/jo401027r  1
2013 Adam Hendricks J, Hanson RN, Amolins M, Mihelcic JM, Blagg BS. Synthesis and preliminary evaluation steroidal antiestrogen-geldanamycin conjugates. Bioorganic & Medicinal Chemistry Letters. 23: 3635-9. PMID 23648180 DOI: 10.1016/J.Bmcl.2013.03.116  1
2013 Patwardhan CA, Fauq A, Peterson LB, Miller C, Blagg BS, Chadli A. Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis. The Journal of Biological Chemistry. 288: 7313-25. PMID 23355466 DOI: 10.1074/Jbc.M112.427328  1
2013 Zhao H, Blagg BS. Novobiocin analogues with second-generation noviose surrogates. Bioorganic & Medicinal Chemistry Letters. 23: 552-7. PMID 23234644 DOI: 10.1016/J.Bmcl.2012.11.022  1
2013 Diaz FJ, McDonald PR, Roy A, Taylor B, Price A, Hall J, Blagg BS, Chaguturu R. Compound ranking based on a new mathematical measure of effectiveness using time course data from cell-based assays. Combinatorial Chemistry & High Throughput Screening. 16: 168-79. PMID 22934946 DOI: 10.2174/1386207311316030002  1
2013 Zeineldin M, McGuinness W, Blagg B, Rajewski R, Neufeld KL. Abstract 2728: Induction of the heat-shock response upregulates the tumor suppressor APC and alters intestinal tumorigenesis in mice. Cancer Research. 73: 2728-2728. DOI: 10.1158/1538-7445.Am2013-2728  1
2012 Zhao H, Moroni E, Yan B, Colombo G, Blagg BS. 3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues. Acs Medicinal Chemistry Letters. 4: 57-62. PMID 23606927 DOI: 10.1021/Ml300275G  1
2012 Zhao H, Yan B, Peterson LB, Blagg BS. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition. Acs Medicinal Chemistry Letters. 3: 327-331. PMID 23316269 DOI: 10.1021/Ml300018E  1
2012 Li C, Ma J, Zhao H, Blagg BS, Dobrowsky RT. Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun. Asn Neuro. 4: e00102. PMID 23240583 DOI: 10.1042/20120047  1
2012 Kusuma BR, Brandt GE, Blagg BS. Synthesis of cruentaren A. Organic Letters. 14: 6242-5. PMID 23205851 DOI: 10.1021/ol302999v  1
2012 Farmer K, Williams SJ, Novikova L, Ramachandran K, Rawal S, Blagg BS, Dobrowsky R, Stehno-Bittel L. KU-32, a novel drug for diabetic neuropathy, is safe for human islets and improves in vitro insulin secretion and viability. Experimental Diabetes Research. 2012: 671673. PMID 23197975 DOI: 10.1155/2012/671673  1
2012 Suntharalingam A, Abisambra JF, O'Leary JC, Koren J, Zhang B, Joe MK, Blair LJ, Hill SE, Jinwal UK, Cockman M, Duerfeldt AS, Tomarev S, Blagg BS, Lieberman RL, Dickey CA. Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism. The Journal of Biological Chemistry. 287: 40661-9. PMID 23035116 DOI: 10.1074/Jbc.M112.384800  1
2012 Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly AC, Yoshida S, Miyajima N, Tsutsumi S, Smith AK, Sun D, Wu X, Blagg BS, Trepel JB, Stetler-Stevenson WG, et al. Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle (Georgetown, Tex.). 11: 3649-55. PMID 22935698 DOI: 10.4161/Cc.21926  1
2012 Zhao H, Michaelis ML, Blagg BS. Hsp90 modulation for the treatment of Alzheimer's disease. Advances in Pharmacology (San Diego, Calif.). 64: 1-25. PMID 22840743 DOI: 10.1016/B978-0-12-394816-8.00001-5  1
2012 Kusuma BR, Zhang L, Sundstrom T, Peterson LB, Dobrowsky RT, Blagg BS. Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity. Journal of Medicinal Chemistry. 55: 5797-812. PMID 22702513 DOI: 10.1021/Jm300544C  1
2012 Duerfeldt AS, Peterson LB, Maynard JC, Ng CL, Eletto D, Ostrovsky O, Shinogle HE, Moore DS, Argon Y, Nicchitta CV, Blagg BS. Development of a Grp94 inhibitor. Journal of the American Chemical Society. 134: 9796-804. PMID 22642269 DOI: 10.1021/Ja303477G  1
2012 Peterson LB, Eskew JD, Vielhauer GA, Blagg BS. The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking. Molecular Pharmaceutics. 9: 1841-6. PMID 22554505 DOI: 10.1021/Mp300138N  1
2012 Urban MJ, Pan P, Farmer KL, Zhao H, Blagg BS, Dobrowsky RT. Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathy. Experimental Neurology. 235: 388-96. PMID 22465570 DOI: 10.1016/J.Expneurol.2012.03.005  1
2012 Zhang L, Zhao H, Blagg BS, Dobrowsky RT. C-terminal heat shock protein 90 inhibitor decreases hyperglycemia-induced oxidative stress and improves mitochondrial bioenergetics in sensory neurons. Journal of Proteome Research. 11: 2581-93. PMID 22413817 DOI: 10.1021/Pr300056M  1
2012 Li K, Frankowski KJ, Belon CA, Neuenswander B, Ndjomou J, Hanson AM, Shanahan MA, Schoenen FJ, Blagg BS, Aubé J, Frick DN. Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline. Journal of Medicinal Chemistry. 55: 3319-30. PMID 22409723 DOI: 10.1021/Jm300021V  1
2012 Urban MJ, Dobrowsky RT, Blagg BS. Heat shock response and insulin-associated neurodegeneration. Trends in Pharmacological Sciences. 33: 129-37. PMID 22172248 DOI: 10.1016/J.Tips.2011.11.001  1
2012 Cohen SM, Mukerji R, Samadi AK, Zhang X, Zhao H, Blagg BS, Cohen MS. Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents. Annals of Surgical Oncology. 19: S483-90. PMID 21837531 DOI: 10.1245/S10434-011-1971-1  1
2012 Woodruff D, Sadikot T, Eskew J, Blagg B, Vielhauer G, Holzbeierlein J. 486 Development Of A High-Throughput Screening Assay For The Identification Of Cancer Cell-Specific Hsp90 The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.555  1
2011 Brandt GE, Blagg BS. Monoenomycin: A Simplified Trienomycin A Analogue that Manifests Anticancer Activity. Acs Medicinal Chemistry Letters. 2: 735-740. PMID 22162786 DOI: 10.1021/ml200108y  1
2011 Eskew JD, Sadikot T, Morales P, Duren A, Dunwiddie I, Swink M, Zhang X, Hembruff S, Donnelly A, Rajewski RA, Blagg BS, Manjarrez JR, Matts RL, Holzbeierlein JM, Vielhauer GA. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. Bmc Cancer. 11: 468. PMID 22039910 DOI: 10.1186/1471-2407-11-468  1
2011 Kusuma BR, Duerfeldt AS, Blagg BS. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorganic & Medicinal Chemistry Letters. 21: 7170-4. PMID 22014546 DOI: 10.1016/J.Bmcl.2011.09.073  1
2011 Samadi AK, Zhang X, Mukerji R, Donnelly AC, Blagg BS, Cohen MS. A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. Cancer Letters. 312: 158-67. PMID 21924824 DOI: 10.1016/J.Canlet.2011.07.031  1
2011 Kusuma BR, Peterson LB, Zhao H, Vielhauer G, Holzbeierlein J, Blagg BS. Targeting the heat shock protein 90 dimer with dimeric inhibitors. Journal of Medicinal Chemistry. 54: 6234-53. PMID 21861487 DOI: 10.1021/Jm200553W  1
2011 Zhao H, Donnelly AC, Kusuma BR, Brandt GE, Brown D, Rajewski RA, Vielhauer G, Holzbeierlein J, Cohen MS, Blagg BS. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. Journal of Medicinal Chemistry. 54: 3839-53. PMID 21553822 DOI: 10.1021/Jm200148P  1
2011 Matts RL, Dixit A, Peterson LB, Sun L, Voruganti S, Kalyanaraman P, Hartson SD, Verkhivker GM, Blagg BS. Elucidation of the Hsp90 C-terminal inhibitor binding site. Acs Chemical Biology. 6: 800-7. PMID 21548602 DOI: 10.1021/Cb200052X  1
2011 Blagg BS, Johnson DS, Garbaccio RM. Recent advances in medicinal chemistry. Bioorganic & Medicinal Chemistry Letters. 21: 2585-6. PMID 21513866 DOI: 10.1016/j.bmcl.2011.04.019  1
2011 Davenport J, Manjarrez JR, Peterson L, Krumm B, Blagg BS, Matts RL. Gambogic acid, a natural product inhibitor of Hsp90. Journal of Natural Products. 74: 1085-92. PMID 21486005 DOI: 10.1021/Np200029Q  1
2011 Zhao H, Brandt GE, Galam L, Matts RL, Blagg BS. Identification and initial SAR of silybin: an Hsp90 inhibitor. Bioorganic & Medicinal Chemistry Letters. 21: 2659-64. PMID 21273068 DOI: 10.1016/J.Bmcl.2010.12.088  1
2011 Matts RL, Brandt GE, Lu Y, Dixit A, Mollapour M, Wang S, Donnelly AC, Neckers L, Verkhivker G, Blagg BS. A systematic protocol for the characterization of Hsp90 modulators. Bioorganic & Medicinal Chemistry. 19: 684-92. PMID 21129982 DOI: 10.1016/J.Bmc.2010.10.029  1
2011 Guarnieri MT, Blagg BS, Zhao R. A high-throughput TNP-ATP displacement assay for screening inhibitors of ATP-binding in bacterial histidine kinases. Assay and Drug Development Technologies. 9: 174-83. PMID 21050069 DOI: 10.1089/adt.2010.0289  1
2011 James A, Holzbeierlein J, Eskew J, Blagg B, Rajewski R, Vielhauer G. 610 In Vivo Efficacy Of Ku-174, A C-Terminal Inhibitor Of Hsp90 In A Pc3 Xenograft Model The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1463  1
2010 Zhao H, Kusuma BR, Blagg BS. Synthesis and Evaluation of Noviose Replacements on Novobiocin that Manifest Anti-proliferative Activity. Acs Medicinal Chemistry Letters. 1: 311-315. PMID 21904660 DOI: 10.1021/Ml100070R  1
2010 Urban MJ, Li C, Yu C, Lu Y, Krise JM, McIntosh MP, Rajewski RA, Blagg BS, Dobrowsky RT. Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice. Asn Neuro. 2: e00040. PMID 20711301 DOI: 10.1042/An20100015  1
2010 Duerfeldt AS, Blagg BS. Hsp90 inhibition: elimination of shock and stress. Bioorganic & Medicinal Chemistry Letters. 20: 4983-7. PMID 20656483 DOI: 10.1016/J.Bmcl.2010.06.108  1
2010 Peterson LB, Blagg BS. Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues. Bioorganic & Medicinal Chemistry Letters. 20: 3957-60. PMID 20570149 DOI: 10.1016/J.Bmcl.2010.04.140  1
2010 Cunningham CW, Mukhopadhyay A, Lushington GH, Blagg BS, Prisinzano TE, Krise JP. Uptake, distribution and diffusivity of reactive fluorophores in cells: implications toward target identification. Molecular Pharmaceutics. 7: 1301-10. PMID 20557111 DOI: 10.1021/Mp100089K  1
2010 Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, et al. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Molecular Cell. 37: 333-43. PMID 20159553 DOI: 10.1016/J.Molcel.2010.01.005  1
2010 Mays JR, Hill SA, Moyers JT, Blagg BS. The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone. Bioorganic & Medicinal Chemistry. 18: 249-66. PMID 19932969 DOI: 10.1016/j.bmc.2009.10.061  1
2010 Matthews SB, Vielhauer GA, Manthe CA, Chaguturu VK, Szabla K, Matts RL, Donnelly AC, Blagg BS, Holzbeierlein JM. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. The Prostate. 70: 27-36. PMID 19739131 DOI: 10.1002/Pros.21035  1
2010 Donnelly AC, Zhao H, Reddy Kusuma B, Blagg BSJ. Cytotoxic sugar analogues of an optimized novobiocin scaffold Medchemcomm. 1: 165-170. DOI: 10.1039/C0Md00063A  1
2009 Peterson LB, Blagg BS. To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Medicinal Chemistry. 1: 267-83. PMID 20161407 DOI: 10.4155/Fmc.09.17  1
2009 Blagg BS. Inhibition and function of heat shock proteins 70 and 90. Current Topics in Medicinal Chemistry. 9: 1335-6. PMID 19925436 DOI: 10.2174/156802609789895746  1
2009 Jadhav VD, Duerfeldt AS, Blagg BS. Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 6845-50. PMID 19896848 DOI: 10.1016/J.Bmcl.2009.10.091  1
2009 Brandt GE, Blagg BS. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Current Topics in Medicinal Chemistry. 9: 1447-61. PMID 19860731 DOI: 10.2174/156802609789895683  1
2009 Shelton SN, Shawgo ME, Matthews SB, Lu Y, Donnelly AC, Szabla K, Tanol M, Vielhauer GA, Rajewski RA, Matts RL, Blagg BS, Robertson JD. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Molecular Pharmacology. 76: 1314-22. PMID 19741006 DOI: 10.1124/Mol.109.058545  1
2009 Hadden MK, Blagg BS. Synthesis and evaluation of radamide analogues, a chimera of radicicol and geldanamycin. The Journal of Organic Chemistry. 74: 4697-704. PMID 19492825 DOI: 10.1021/jo900278g  1
2009 Duerfeldt AS, Brandt GE, Blagg BS. Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors. Organic Letters. 11: 2353-6. PMID 19435295 DOI: 10.1021/Ol900783M  1
2009 Duerfeldt AS, Blagg BS. Hydrating for resistance to radicicol. Acs Chemical Biology. 4: 245-7. PMID 19371133 DOI: 10.1021/Cb9000712  1
2009 Immormino RM, Metzger LE, Reardon PN, Dollins DE, Blagg BS, Gewirth DT. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design. Journal of Molecular Biology. 388: 1033-42. PMID 19361515 DOI: 10.1016/J.Jmb.2009.03.071  1
2009 Amolins MW, Blagg BS. Natural product inhibitors of Hsp90: potential leads for drug discovery. Mini Reviews in Medicinal Chemistry. 9: 140-52. PMID 19200020 DOI: 10.2174/138955709787316056  1
2009 Lu Y, Ansar S, Michaelis ML, Blagg BS. Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line. Bioorganic & Medicinal Chemistry. 17: 1709-15. PMID 19138859 DOI: 10.1016/J.Bmc.2008.12.047  1
2009 Hadden MK, Hill SA, Davenport J, Matts RL, Blagg BS. Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold. Bioorganic & Medicinal Chemistry. 17: 634-40. PMID 19101151 DOI: 10.1016/J.Bmc.2008.11.064  1
2009 Amolins MW, Peterson LB, Blagg BS. Synthesis and evaluation of electron-rich curcumin analogues. Bioorganic & Medicinal Chemistry. 17: 360-7. PMID 19019687 DOI: 10.1016/J.Bmc.2008.10.057  1
2008 Wang M, Blagg BS. Synthesis of a versatile metacyclophane macrolactam. Tetrahedron Letters. 49: 141-144. PMID 19568319 DOI: 10.1016/j.tetlet.2007.10.150  1
2008 Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Current Medicinal Chemistry. 15: 2702-17. PMID 18991631 DOI: 10.2174/092986708786242895  1
2008 Donnelly AC, Mays JR, Burlison JA, Nelson JT, Vielhauer G, Holzbeierlein J, Blagg BS. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. The Journal of Organic Chemistry. 73: 8901-20. PMID 18939877 DOI: 10.1021/Jo801312R  1
2008 Hadden MK, Blagg BS. Dimeric approaches to anti-cancer chemotherapeutics. Anti-Cancer Agents in Medicinal Chemistry. 8: 807-16. PMID 18855582  1
2008 Brandt GE, Schmidt MD, Prisinzano TE, Blagg BS. Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. Journal of Medicinal Chemistry. 51: 6495-502. PMID 18816111 DOI: 10.1021/Jm8007486  1
2008 Burlison JA, Avila C, Vielhauer G, Lubbers DJ, Holzbeierlein J, Blagg BS. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. The Journal of Organic Chemistry. 73: 2130-7. PMID 18293999 DOI: 10.1021/Jo702191A  1
2008 Tash JS, Chakrasali R, Jakkaraj SR, Hughes J, Smith SK, Hornbaker K, Heckert LL, Ozturk SB, Hadden MK, Kinzy TG, Blagg BS, Georg GI. Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and stimulates Il1a transcription in rat Sertoli cells. Biology of Reproduction. 78: 1139-52. PMID 18218611 DOI: 10.1095/Biolreprod.107.062679  1
2008 Hastings JM, Hadden MK, Blagg BS. Synthesis and evaluation of derrubone and select analogues. The Journal of Organic Chemistry. 73: 369-73. PMID 18154304 DOI: 10.1021/jo702366g  1
2007 Hadden MK, Galam L, Gestwicki JE, Matts RL, Blagg BS. Derrubone, an inhibitor of the Hsp90 protein folding machinery. Journal of Natural Products. 70: 2014-8. PMID 18020309 DOI: 10.1021/Np070190S  1
2007 Bishop SC, Burlison JA, Blagg BS. Hsp90: a novel target for the disruption of multiple signaling cascades. Current Cancer Drug Targets. 7: 369-88. PMID 17979631 DOI: 10.2174/156800907780809778  1
2007 Hadden MK, Blagg BS. Cytotoxic small molecule dimers and their inhibitory activity against human breast cancer cells. Bioorganic & Medicinal Chemistry Letters. 17: 5063-7. PMID 17656092 DOI: 10.1016/j.bmcl.2007.07.014  1
2007 Huang YT, Blagg BS. A library of noviosylated coumarin analogues. The Journal of Organic Chemistry. 72: 3609-13. PMID 17328573 DOI: 10.1021/jo062083t  1
2007 Ansar S, Burlison JA, Hadden MK, Yu XM, Desino KE, Bean J, Neckers L, Audus KL, Michaelis ML, Blagg BS. A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorganic & Medicinal Chemistry Letters. 17: 1984-90. PMID 17276679 DOI: 10.1016/J.Bmcl.2007.01.017  1
2007 Galam L, Hadden MK, Ma Z, Ye QZ, Yun BG, Blagg BS, Matts RL. High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase. Bioorganic & Medicinal Chemistry. 15: 1939-46. PMID 17223347 DOI: 10.1016/J.Bmc.2007.01.004  1
2006 Duvvuri M, Konkar S, Hong KH, Blagg BS, Krise JP. A new approach for enhancing differential selectivity of drugs to cancer cells. Acs Chemical Biology. 1: 309-15. PMID 17163760 DOI: 10.1021/Cb6001202  1
2006 Burlison JA, Neckers L, Smith AB, Maxwell A, Blagg BS. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. Journal of the American Chemical Society. 128: 15529-36. PMID 17132020 DOI: 10.1021/Ja065793P  1
2006 Chaudhury S, Welch TR, Blagg BS. Hsp90 as a target for drug development. Chemmedchem. 1: 1331-40. PMID 17066389 DOI: 10.1002/Cmdc.200600112  1
2006 Burlison JA, Blagg BS. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery. Organic Letters. 8: 4855-8. PMID 17020320 DOI: 10.1021/Ol061918J  1
2006 Shen G, Wang M, Welch TR, Blagg BS. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90. The Journal of Organic Chemistry. 71: 7618-31. PMID 16995666 DOI: 10.1021/Jo061054F  1
2006 Elliott GI, Fuchs JR, Blagg BS, Ishikawa H, Tao H, Yuan ZQ, Boger DL. Intramolecular diels-alder/1,3-dipolar cycloaddition cascade of 1,3,4-oxadiazoles. Journal of the American Chemical Society. 128: 10589-95. PMID 16895427 DOI: 10.1021/Ja0612549  1
2006 Hadden MK, Lubbers DJ, Blagg BS. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Current Topics in Medicinal Chemistry. 6: 1173-82. PMID 16842154 DOI: 10.2174/156802606777812031  1
2006 Avila C, Hadden MK, Ma Z, Kornilayev BA, Ye QZ, Blagg BS. High-throughput screening for Hsp90 ATPase inhibitors. Bioorganic & Medicinal Chemistry Letters. 16: 3005-8. PMID 16530412 DOI: 10.1016/j.bmcl.2006.02.063  1
2006 Peng W, Blagg BS. A versatile approach toward the ansamycin antibiotics. Organic Letters. 8: 975-8. PMID 16494488 DOI: 10.1021/ol060022b  1
2006 Wang M, Shen G, Blagg BS. Radanamycin, a macrocyclic chimera of radicicol and geldanamycin. Bioorganic & Medicinal Chemistry Letters. 16: 2459-62. PMID 16464590 DOI: 10.1016/J.Bmcl.2006.01.086  1
2006 Blagg BS, Kerr TD. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Medicinal Research Reviews. 26: 310-38. PMID 16385472 DOI: 10.1002/med.20052  1
2006 Avila C, Kornilayev BA, Blagg BS. Development and optimization of a useful assay for determining Hsp90's inherent ATPase activity. Bioorganic & Medicinal Chemistry. 14: 1134-42. PMID 16213144 DOI: 10.1016/j.bmc.2005.09.027  1
2005 Yu XM, Shen G, Neckers L, Blake H, Holzbeierlein J, Cronk B, Blagg BS. Hsp90 inhibitors identified from a library of novobiocin analogues. Journal of the American Chemical Society. 127: 12778-9. PMID 16159253 DOI: 10.1021/Ja0535864  1
2005 Yu XM, Han H, Blagg BS. Synthesis of mono- and dihydroxylated furanoses, pyranoses, and an oxepanose for the preparation of natural product analogue libraries. The Journal of Organic Chemistry. 70: 5599-605. PMID 15989342 DOI: 10.1021/Jo050558V  1
2005 Shen G, Blagg BS. Radester, a novel inhibitor of the Hsp90 protein folding machinery. Organic Letters. 7: 2157-60. PMID 15901158 DOI: 10.1021/Ol050580A  1
2004 Clevenger RC, Blagg BS. Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide. Organic Letters. 6: 4459-62. PMID 15548050 DOI: 10.1021/Ol048266O  1
2004 Shen G, Yu XM, Blagg BS. Syntheses of photolabile novobiocin analogues. Bioorganic & Medicinal Chemistry Letters. 14: 5903-6. PMID 15501066 DOI: 10.1016/J.Bmcl.2004.09.017  1
2004 Yu XM, Shen G, Blagg BS. Synthesis of (-)-noviose from 2,3-O-isopropylidene-D-erythronolactol. The Journal of Organic Chemistry. 69: 7375-8. PMID 15471498 DOI: 10.1021/Jo048953T  1
2004 Clevenger RC, Raibel JM, Peck AM, Blagg BS. Biotinylated geldanamycin. The Journal of Organic Chemistry. 69: 4375-80. PMID 15202892 DOI: 10.1021/jo049848m  1
2002 Wilkie GD, Elliott GI, Blagg BS, Wolkenberg SE, Soenen DR, Miller MM, Pollack S, Boger DL. Intramolecular Diels-Alder and tandem intramolecular Diels-Alder/1,3-dipolar cycloaddition reactions of 1,3,4-oxadiazoles. Journal of the American Chemical Society. 124: 11292-4. PMID 12236743 DOI: 10.1021/Ja027533N  1
2002 Blagg BS, Jarstfer MB, Rogers DH, Poulter CD. Recombinant squalene synthase. A mechanism for the rearrangement of presqualene diphosphate to squalene. Journal of the American Chemical Society. 124: 8846-53. PMID 12137537 DOI: 10.1021/Ja020411A  1
2002 Koppisch AT, Fox DT, Blagg BS, Poulter CD. E. coli MEP synthase: steady-state kinetic analysis and substrate binding. Biochemistry. 41: 236-43. PMID 11772021 DOI: 10.1021/Bi0118207  1
2002 Blagg BSJ, Boger DL. Total synthesis of (+)-camptothecin Tetrahedron. 58: 6343-6349. DOI: 10.1016/S0040-4020(02)00633-6  1
2001 Hahn FM, Eubanks LM, Testa CA, Blagg BS, Baker JA, Poulter CD. 1-Deoxy-D-xylulose 5-phosphate synthase, the gene product of open reading frame (ORF) 2816 and ORF 2895 in Rhodobacter capsulatus. Journal of Bacteriology. 183: 1-11. PMID 11114895 DOI: 10.1128/Jb.183.1.1-11.2001  1
2000 Koppisch AT, Blagg BS, Poulter CD. Synthesis of 2-C-methyl-D-erythritol 4-phosphate: the first pathway-specific intermediate in the methylerythritol phosphate route to isoprenoids. Organic Letters. 2: 215-7. PMID 10814285 DOI: 10.1021/Ol991299X  1
1999 Blagg BS, Poulter CD. Synthesis of 1-Deoxy-D-xylulose and 1-Deoxy-D-xylulose-5-phosphate. The Journal of Organic Chemistry. 64: 1508-1511. PMID 11674212 DOI: 10.1021/Jo981966K  1
1996 Jarstfer MB, Blagg BSJ, Rogers DH, Poulter CD. Biosynthesis of squalene. Evidence for a tertiary cyclopropylcarbinyl cationic intermediate in the rearrangement of presqualene disphosphate to squalene Journal of the American Chemical Society. 118: 13089-13090. DOI: 10.1021/Ja963308S  1
Show low-probability matches.